# Shanghai Junsai Biotechnology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shanghai-junsai-biotechnology

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Latest round: Series B (Aug 7, 2025)
- Investors on record: 13

## About

Based in Shanghai, China and established in 2019, Shanghai Junsai Biotechnology is a tumor cell therapy developer that focuses on Tumor Infiltrating Lymphocyte and related drugs. The company has completed 4 rounds of funding as of 2022.

The company's main business is development of innovative tumor infiltrating lymphocyte (TIL) based therapies for solid tumors and First-in-class/Best-in-class cell-based novel drugs. The products used in the field of recurrent refractory malignancies.

## Funding rounds

- Series B, Aug 7, 2025 — Oriza Holdings, Jiading Venture Capital, Shanghai You Ze Enterprise, Hangzhou Smart Cloud Map
- Series A, Jan 15, 2022 — Oriza Holdings, Kaitai Capital, YuanBio Venture, HY Capital, Huaige Capital, ALAN AMC, Huangpu Pharmaceutical Fund
- Series A, Oct 27, 2021 — Oriza Holdings, Kaitai Capital, MED-FINE Capital, Furong Capital, Huaige Capital
- Series A, Feb 26, 2021 — Kaitai Capital, MED-FINE Capital, Shanghai Furong Investment

## Investors

- Kaitai Capital (https://capitalatlas.ai/funds/kaitai-capital) — Series A
- MED-FINE Capital (https://capitalatlas.ai/funds/med-fine-capital) — Series A
- Shanghai Furong Investment — Series A
- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Series A, Series B
- Furong Capital (https://capitalatlas.ai/funds/furong-capital) — Series A
- Huaige Capital (https://capitalatlas.ai/funds/huaige-capital) — Series A
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series A
- HY Capital (https://capitalatlas.ai/funds/hy-capital) — Series A
- ALAN AMC (https://capitalatlas.ai/funds/alan-amc) — Series A
- Huangpu Pharmaceutical Fund — Series A
- Jiading Venture Capital (https://capitalatlas.ai/funds/jiading-venture-capital) — Series B
- Shanghai You Ze Enterprise — Series B
- Hangzhou Smart Cloud Map — Series B